Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Integra Lifesciences Holdings (IART) Equity Ratio (2016 - 2025)

Integra Lifesciences Holdings' Equity Ratio history spans 17 years, with the latest figure at 0.29 for Q4 2025.

  • For Q4 2025, Equity Ratio fell 24.31% year-over-year to 0.29; the TTM value through Dec 2025 reached 0.29, down 24.31%, while the annual FY2025 figure was 0.29, 24.31% down from the prior year.
  • Equity Ratio for Q4 2025 was 0.29 at Integra Lifesciences Holdings, up from 0.28 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.46 in Q4 2022 and bottomed at 0.28 in Q2 2025.
  • The 5-year median for Equity Ratio is 0.42 (2023), against an average of 0.4.
  • The largest annual shift saw Equity Ratio grew 6.65% in 2021 before it decreased 24.79% in 2025.
  • A 5-year view of Equity Ratio shows it stood at 0.45 in 2021, then grew by 4.14% to 0.46 in 2022, then fell by 9.49% to 0.42 in 2023, then decreased by 8.84% to 0.38 in 2024, then dropped by 24.31% to 0.29 in 2025.
  • Per Business Quant, the three most recent readings for IART's Equity Ratio are 0.29 (Q4 2025), 0.28 (Q3 2025), and 0.28 (Q2 2025).